C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 6.83 HKD -2.01% Market Closed
Market Cap: 2.2B HKD
Have any thoughts about
Cutia Therapeutics?
Write Note

EV/EBIT
Enterprise Value to EBIT

-2.1
Current
-3.7
Median
4
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-2.1
=
Enterprise Value
1.2B HKD
/
EBIT
-535.5m CNY
All Countries
Close
Market Cap EV/EBIT
CN
Cutia Therapeutics
HKEX:2487
2.1B HKD -2.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -217 039.4
US
Abbvie Inc
NYSE:ABBV
310.3B USD 23.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 22.1
US
Epizyme Inc
F:EPE
94.1B EUR -500.9
AU
CSL Ltd
ASX:CSL
133.7B AUD 24.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 16.7
US
Seagen Inc
F:SGT
39.3B EUR -53
NL
argenx SE
XBRU:ARGX
36.2B EUR -80.2
EBIT Growth EV/EBIT to Growth
CN
C
Cutia Therapeutics
HKEX:2487
Average EV/EBIT: 21.2
Negative Multiple: -2.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 039.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.9 N/A N/A
AU
CSL Ltd
ASX:CSL
24.4
54%
0.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -80.2 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-2.3
2-Years Forward
EV/EBIT
-3
3-Years Forward
EV/EBIT
-5.7

See Also

Discover More